Clinical Trials Browser

Leukemia, Myelomonocytic, Chronic × ruxolitinib × 90 days × Clear all

NCT03722407 2026-04-02

Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion

Phase 2 Active not recruiting

29 enrolled 11 charts

Other hematologic neoplasm

Leukemia, Leukemia, Myelomonocytic, Chronic